Form 8-K
8-K — MOLINA HEALTHCARE, INC.
Accession: 0001179929-26-000020
Filed: 2026-04-22
Period: 2026-04-22
CIK: 0001179929
SIC: 6324 (HOSPITAL & MEDICAL SERVICE PLANS)
Item: Results of Operations and Financial Condition
Item: Financial Statements and Exhibits
Documents
8-K — moh-20260422.htm (Primary)
EX-99.1 (moh1q26_er.htm)
GRAPHIC (molinaa03a01a01a17.jpg)
XML — IDEA: XBRL DOCUMENT (R1.htm)
8-K
8-K (Primary)
Filename: moh-20260422.htm · Sequence: 1
moh-20260422
0001179929false00011799292026-04-222026-04-22
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
______________
FORM 8-K
______________
Current Report
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 22, 2026
______________
MOLINA HEALTHCARE, INC.
(Exact name of registrant as specified in its charter)
Delaware 1-31719 13-4204626
(State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.)
______________
200 Oceangate, Suite 100, Long Beach, California 90802
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: (562) 435-3666
N/A
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, $0.001 Par Value MOH New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section13(a) of the Exchange Act.
☐
Item 2.02. Results of Operations and Financial Condition.
On April 22, 2026, Molina Healthcare, Inc. (the “Company”) issued a press release reporting its financial results for the first quarter ended March 31, 2026 and reaffirming the Company’s full-year 2026 premium revenue and adjusted earnings guidance. The full text of the press release is included as Exhibit 99.1 to this report. The information contained in the Company’s website cited in the press release is not part of this report.
Note: The information in this Form 8-K and the exhibits attached hereto shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits:
Exhibit No. Description
99.1
Press release of Molina Healthcare, Inc., issued April 22, 2026.
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
MOLINA HEALTHCARE, INC.
Date:
April 22, 2026
By:
/s/ Jeff D. Barlow
Jeff D. Barlow
Chief Legal Officer and Secretary
EX-99.1
EX-99.1
Filename: moh1q26_er.htm · Sequence: 2
Document
News Release
Investor Contact: Jeffrey Geyer, Jeffrey.Geyer@molinahealthcare.com, 305-317-3012
Media Contact: Caroline Zubieta, Caroline.Zubieta@molinahealthcare.com, 562-951-1588
Molina Healthcare Reports First Quarter 2026 Financial Results
Reaffirms Full Year 2026 Premium Revenue and Adjusted Earnings Guidance
Long Beach, Calif., April 22, 2026 – Molina Healthcare, Inc. (NYSE: MOH) (the “Company”) today reported first quarter 2026 GAAP income per diluted share of $0.27 and adjusted income per diluted share of $2.35. Financial results are summarized below:
Three months ended
March 31,
2026 2025
(In millions, except per-share results)
Premium Revenue $10,172 $10,628
Total Revenue $10,796 $11,147
GAAP:
Net Income $14 $298
EPS – Diluted $0.27 $5.45
Medical Care Ratio (MCR) 91.1 % 89.2 %
G&A Ratio 7.2 % 6.9 %
Pre-tax Margin 0.3 % 3.5 %
Adjusted:
Net Income $120 $333
EPS – Diluted $2.35 $6.08
G&A Ratio 6.9 % 6.3 %
Pre-tax Margin 1.6 % 3.9 %
See the Reconciliation of Unaudited Non-GAAP Financial Measures at the end of this release.
Quarter Highlights
•As of March 31, 2026, the Company served approximately 5.0 million members.
•Premium revenue was approximately $10.2 billion for the first quarter of 2026.
•First quarter 2026 GAAP income per diluted share of $0.27 and adjusted income per diluted share of $2.35.
•The Company reaffirmed its full year 2026 guidance of expected premium revenue of approximately $42 billion and adjusted earnings of at least $5.00 per diluted share.
“We are pleased with our first quarter results and continued disciplined approach to medical cost management,” said Joseph Zubretsky, President and Chief Executive Officer. “Medical cost trend was modestly favorable to our expectations, and our reaffirmed full year 2026 premium revenue and adjusted earnings guidance reflect a prudent view of full year results at this early point in the year. We look forward to updating you on our three-year outlook at our Investor Day event on Friday, May 8th.”
-MORE-
Molina Healthcare, Inc. Reports First Quarter 2026 Financial Results
Page 2
April 22, 2026
Premium Revenue
Premium revenue was approximately $10.2 billion for the first quarter of 2026, a decrease of 4% year over year. The lower premium revenue reflects the impact of lower Medicaid membership due to general market contraction and the expiration of our Medicaid contract in Virginia, and a decrease in Marketplace membership resulting from our product and pricing strategy.
Net Income
GAAP net income for the first quarter of 2026 was $0.27 per diluted share, a decrease of 95% year over year, and reflects a $93 million impairment of intangible assets related to the Company’s planned exit of the Medicare Advantage-Part D product for 2027. Adjusted net income for the first quarter of 2026 was $2.35 per diluted share, a decrease of 61% year over year.
Medical Care Ratio (MCR)
•The consolidated MCR for the first quarter of 2026 was 91.1%.
•The Medicaid MCR for the first quarter of 2026 was 92.0%, reflecting the January 1st rate cycle and medical cost trend that was moderately favorable to the Company’s expectations.
•The Medicare MCR for the first quarter of 2026 was 89.8%, and in line with the Company’s expectation, reflecting pricing and benefit adjustments implemented for 2026.
•The Marketplace MCR for the first quarter of 2026 was 84.0%. Within that result, approximately 450 basis points was due to prior year risk adjustment and continued program integrity initiatives by the Centers for Medicare and Medicaid Services. Excluding these items, the Marketplace MCR was approximately 79.5% and in line with the Company’s expectations.
General and Administrative Expense Ratio
The G&A ratio and the adjusted G&A ratio for the first quarter of 2026 were 7.2% and 6.9%, respectively, and reflect the timing of operating expenses.
Balance Sheet
Cash and investments at the parent company were approximately $213 million as of March 31, 2026, compared to $223 million as of December 31, 2025.
Days in claims payable at March 31, 2026, was 44, lower than typical due to the timing of payments at the end of the quarter.
Cash Flow
Operating cash flow for the three months ended March 31, 2026, was $1,082 million, compared to $190 million for the three months ended March 31, 2025. The increase in cash flow for the period year-over-year was driven mainly by the timing of government receivables and payables.
2026 Guidance
Premium revenue guidance for the full year is unchanged and expected to be approximately $42 billion, a decline of approximately 2% from the full year 2025.
The Company expects its full year 2026 GAAP earnings to be at least $1.90 per diluted share and reaffirms its full year 2026 adjusted earnings of at least $5.00 per diluted share. When the Company reports its second quarter of 2026 results, it expects to update full year 2026 guidance to reflect the first and second quarter results, which provide a time-tested base off of which to project the second half of 2026.
-MORE-
Molina Healthcare, Inc. Reports First Quarter 2026 Financial Results
Page 3
April 22, 2026
Conference Call
Management will host a conference call and webcast to discuss Molina Healthcare’s first quarter March 31, 2026 results, at 8:00 a.m. Eastern Time on Thursday, April 23, 2026. The number to call for the interactive teleconference is (877) 883-0383 and the confirmation number is 4352622. A telephonic replay of the conference call will be available through Thursday, April 30, 2026, by dialing (855) 669-9658 and entering confirmation number 6456388. A live audio broadcast of this conference call will be available on Molina Healthcare’s investor relations website, investors.molinahealthcare.com. A 30-day online replay will be available approximately an hour following the conclusion of the live broadcast.
About Molina Healthcare
Molina Healthcare, Inc., a FORTUNE 500 company, provides managed healthcare services under the Medicaid and Medicare programs and through the state insurance marketplaces. For more information about Molina Healthcare, please visit molinahealthcare.com.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
This earnings release and the Company’s accompanying oral remarks contain forward-looking statements. The Company intends such forward-looking statements to be covered under the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements provide current expectations of future events based on certain assumptions, and all statements other than statements of historical fact contained in this earnings release and the Company’s accompanying oral remarks may be forward-looking statements. In some cases, you can identify forward-looking statements by words such as “guidance,” “future,” “anticipates,” “believes,” “embedded,” “estimates,” “expects,” “growth,” “intends,” “plans,” “predicts,” “projects,” “will,” “would,” “could,” “can,” “may,” or the negative of these terms or other similar expressions. Forward-looking statements contained in this earnings release include, but are not limited to, statements regarding the Company’s 2026 guidance and long-term performance outlook, trends with respect to rates, utilization, and medical costs, including the timing thereof and the anticipated impact on the Company’s business, and our management’s plans and objectives for future operations and business strategy.
Actual results could differ materially due to numerous known and unknown risks and uncertainties. These risks and uncertainties are discussed under the headings “Forward-Looking Statements,” and “Risk Factors,” in the Company’s Annual Report on Form 10‑K for the year ended December 31, 2025, which is on file with the U.S. Securities and Exchange Commission (the “SEC”), and in the Company’s other filings with the SEC, including its Quarterly Report on Form 10-Q for the period ended March 31, 2026, to be filed with the SEC.
These reports can be accessed under the investor relations tab of the Company’s website or on the SEC’s website at sec.gov. Given these risks and uncertainties, the Company can give no assurances that its forward-looking statements will prove to be accurate, or that any other results or developments projected or contemplated by its forward-looking statements will in fact occur, and the Company cautions investors not to place undue reliance on these statements. All forward-looking statements in this release represent the Company’s judgment as of April 22, 2026, and, except as otherwise required by law, the Company disclaims any obligation to update any forward-looking statement to conform the statement to actual results or changes in its expectations.
-MORE-
Molina Healthcare, Inc. Reports First Quarter 2026 Financial Results
Page 4
April 22, 2026
MOLINA HEALTHCARE, INC.
UNAUDITED CONSOLIDATED STATEMENTS OF INCOME
Three Months Ended
March 31,
2026 2025
(In millions, except per-share amounts)
Revenue:
Premium revenue $ 10,172 $ 10,628
Premium tax revenue 504 388
Investment income 98 108
Other revenue 22 23
Total revenue 10,796 11,147
Operating expenses:
Medical care costs 9,270 9,479
General and administrative expenses 779 774
Premium tax expenses 504 388
Depreciation and amortization 39 48
Impairment 93 —
Other 28 25
Total operating expenses 10,713 10,714
Operating income 83 433
Interest expense 54 43
Income before income tax expense 29 390
Income tax expense 15 92
Net income $ 14 $ 298
Net income per share – Diluted $ 0.27 $ 5.45
Diluted weighted average shares outstanding
51.0 54.8
-MORE-
Molina Healthcare, Inc. Reports First Quarter 2026 Financial Results
Page 5
April 22, 2026
MOLINA HEALTHCARE, INC.
CONSOLIDATED BALANCE SHEETS
March 31, December 31,
2026 2025
Unaudited
(Dollars in millions,
except per-share amounts)
ASSETS
Current assets:
Cash and cash equivalents $ 5,314 $ 4,248
Investments 3,937 4,008
Receivables 3,420 3,533
Prepaid expenses and other current assets 655 655
Total current assets 13,326 12,444
Property, equipment, and capitalized software, net 300 301
Goodwill and intangible assets, net 2,092 2,195
Restricted investments 312 299
Deferred income taxes, net 215 178
Other assets 146 147
Total assets $ 16,391 $ 15,564
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Medical claims and benefits payable $ 4,941 $ 4,887
Amounts due government agencies 1,685 1,326
Accounts payable, accrued liabilities and other 1,161 1,093
Deferred revenue 401 66
Total current liabilities 8,188 7,372
Long-term debt 3,767 3,766
Finance lease liabilities 180 184
Other long-term liabilities 176 173
Total liabilities 12,311 11,495
Stockholders’ equity:
Common stock, $0.001 par value, 150 million shares authorized; outstanding: 52 million shares at March 31, 2026, and 51 million at December 31, 2025
— —
Preferred stock, $0.001 par value; 20 million shares authorized, no shares issued and outstanding
— —
Additional paid-in capital 471 452
Accumulated other comprehensive (loss) income (7) 15
Retained earnings 3,616 3,602
Total stockholders’ equity 4,080 4,069
Total liabilities and stockholders’ equity $ 16,391 $ 15,564
-MORE-
Molina Healthcare, Inc. Reports First Quarter 2026 Financial Results
Page 6
April 22, 2026
MOLINA HEALTHCARE, INC.
UNAUDITED CONSOLIDATED STATEMENTS OF CASH FLOWS
Three Months Ended
March 31,
2026 2025
(In millions)
Operating activities:
Net income $ 14 $ 298
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization 39 48
Deferred income taxes (30) 13
Share-based compensation
33 27
Impairment 93 —
Other, net
— 2
Changes in operating assets and liabilities:
Receivables 113 (90)
Prepaid expenses and other current assets (86) (56)
Medical claims and benefits payable 54 (81)
Amounts due government agencies 359 (32)
Accounts payable, accrued liabilities and other 79 (268)
Deferred revenue 335 252
Income taxes 79 77
Net cash provided by operating activities 1,082 190
Investing activities:
Purchases of investments (249) (189)
Proceeds from sales and maturities of investments
295 331
Purchases of property, equipment, and capitalized software
(27) (22)
Net cash paid in business combinations — (245)
Other, net (8) 2
Net cash provided by (used in) investing activities 11 (123)
Financing activities:
Proceeds from borrowings under credit facility and term loans — 650
Common stock purchases
— (500)
Common stock withheld to settle employee tax obligations (14) (36)
Other, net (6) 33
Net cash (used in) provided by financing activities (20) 147
Net increase in cash, cash equivalents, and restricted cash and cash equivalents 1,073 214
Cash, cash equivalents, and restricted cash and cash equivalents at beginning of period
4,348 4,741
Cash, cash equivalents, and restricted cash and cash equivalents at end of period
$ 5,421 $ 4,955
-MORE-
Molina Healthcare, Inc. Reports First Quarter 2026 Financial Results
Page 7
April 22, 2026
MOLINA HEALTHCARE, INC.
UNAUDITED SEGMENT DATA
(Dollars in millions)
March 31, December 31, March 31,
2026
2025
2025
Ending Membership by Segment:
Medicaid 4,498,000 4,568,000 4,812,000
Medicare 229,000 262,000 260,000
Marketplace 305,000 655,000 662,000
Other 2,000 6,000 18,000
Total 5,034,000 5,491,000 5,752,000
Three Months Ended March 31,
2026 2025
Premium Revenue Medical
Margin
MCR (1)
Premium Revenue Medical
Margin
MCR (1)
Medicaid $ 7,927 $ 631 92.0 % $ 8,130 $ 791 90.3 %
Medicare 1,517 154 89.8 1,468 172 88.3
Marketplace 724 116 84.0 1,004 183 81.7
Other 4 1 88.4 26 3 87.7
Consolidated $ 10,172 $ 902 91.1 % $ 10,628 $ 1,149 89.2 %
(1)The MCR represents medical costs as a percentage of premium revenue.
-MORE-
Molina Healthcare, Inc. Reports First Quarter 2026 Financial Results
Page 8
April 22, 2026
MOLINA HEALTHCARE, INC.
CHANGE IN MEDICAL CLAIMS AND BENEFITS PAYABLE
(Dollars in millions)
The Company’s claims liabilities include additional reserves to account for moderately adverse conditions based on historical experience and other factors including, but not limited to, variations in claims payment patterns, changes in utilization and cost trends, known outbreaks of disease, and large claims. The Company’s reserving methodology is consistently applied across all periods presented. The amounts displayed for “Components of medical care costs related to: Prior year” represent the amounts by which the original estimates of claims and benefits payable at the beginning of the year were more than the actual liabilities based on information (principally the payment of claims) developed since those liabilities were first reported. The following table presents the components of the change in medical claims and benefits payable for the periods indicated:
Three Months Ended
March 31,
2026 2025
Unaudited
Medical claims and benefits payable, beginning balance
$ 4,887 $ 4,640
Components of medical care costs related to:
Current year 9,523 9,665
Prior year (253) (186)
Total medical care costs 9,270 9,479
Payments for medical care costs related to:
Current year 5,883 5,789
Prior year 3,628 3,684
Total paid 9,511 9,473
Acquired balances, net of post-acquisition adjustments — 245
Change in non-risk and other payables 295 (87)
Medical claims and benefits payable, ending balance
$ 4,941 $ 4,804
Days in Claims Payable (1)
44 46
__________________
(1)The Company calculates Days in Claims Payable using claims incurred but not paid, or IBNP, and other fee-for-service payables included in medical claims and benefits payable, and quarterly fee-for-service related costs included in medical care costs within the Company’s consolidated financial statements.
-MORE-
Molina Healthcare, Inc. Reports First Quarter 2026 Financial Results
Page 9
April 22, 2026
MOLINA HEALTHCARE, INC.
RECONCILIATION OF UNAUDITED NON-GAAP FINANCIAL MEASURES
(In millions, except per diluted share amounts)
The Company believes that certain non-GAAP (generally accepted accounting principles) financial measures are useful supplemental measures to investors in comparing the Company’s performance to the performance of other public companies in the health care industry. The non-GAAP financial measures are also used internally to enable management to assess the Company’s performance consistently over time. These non-GAAP financial measures, presented below, should be considered as supplements to, and not as substitutes for or superior to, GAAP measures.
Adjustments represent additions and deductions to GAAP net income as indicated in the table below, which include the non-cash impact of amortization of acquired intangible assets, acquisition-related expenses, impairments, and the impact of certain expenses and other items that management believes are not indicative of longer-term business trends and operations.
Adjusted G&A Ratio represents the GAAP G&A ratio, recognizing adjustments.
Adjusted net income represents GAAP net income recognizing the adjustments, net of tax. The Company believes that adjusted net income is helpful to investors in assessing the Company’s financial performance.
Adjusted net income per diluted share represents adjusted net income divided by weighted average common shares outstanding on a fully diluted basis.
Adjusted pre-tax margin represents adjusted income before income tax expense, divided by total revenue.
Three Months Ended March 31,
2026 2025
Amount Per Diluted Share Amount Per Diluted Share
GAAP Net income
$ 14 $ 0.27 $ 298 $ 5.45
Adjustments:
Amortization of intangible assets
$ 10 $ 0.20 $ 21 $ 0.39
Acquisition-related expenses (1)
21 0.41 23 0.41
Impairment (2)
93 1.83 — —
Other (3)
21 0.41 2 0.03
Subtotal, adjustments
145 2.85 46 0.83
Income tax effect
(39) (0.77) (11) (0.20)
Adjustments, net of tax
106 2.08 35 0.63
Adjusted net income
$ 120 $ 2.35 $ 333 $ 6.08
__________________
(1)Reflects non-recurring costs associated with acquisitions, including various transaction and certain integration costs.
(2)This impairment charge results from the Company’s decision to exit the Medicare Advantage Prescription Drug product for 2027 as that product does not align with the Company’s strategic shift to focus exclusively on dual eligible members in Medicare.
(3)The three months ended March 31, 2026 primarily includes non-recurring termination benefits, and the three months ended March 31, 2025 includes non-recurring litigation costs.
-MORE-
Molina Healthcare, Inc. Reports First Quarter 2026 Financial Results
Page 10
April 22, 2026
MOLINA HEALTHCARE, INC.
RECONCILIATION OF UNAUDITED NON-GAAP FINANCIAL MEASURES (CONTINUED)
2026 GUIDANCE
Amount
Per Diluted Share (2)
GAAP Net income
$ 97 $ 1.90
Adjustments:
Acquisition-related expenses
66 1.28
Amortization of intangible assets 36 0.71
Impairment 93 1.83
Other 21 0.41
Subtotal, adjustments
216 4.23
Income tax effect (1)
(57) (1.13)
Adjustments, net of tax
159 3.10
Adjusted net income
$ 256 $ 5.00
__________________
(1)Income tax effect calculated at the statutory tax rate of approximately 26.8%.
(2)Computations assume approximately 51.1 million diluted weighted average shares outstanding.
-END-
GRAPHIC
GRAPHIC
Filename: molinaa03a01a01a17.jpg · Sequence: 6
Binary file (79878 bytes)
Download molinaa03a01a01a17.jpg
XML — IDEA: XBRL DOCUMENT
XML
Filename: R1.htm · Sequence: 8
v3.26.1
Cover Page Document
Apr. 22, 2026
Cover [Abstract]
Entity Central Index Key
0001179929
Document Type
8-K
Entity Emerging Growth Company
false
Title of 12(b) Security
Common Stock, $0.001 Par Value
Entity Incorporation, State or Country Code
DE
Entity File Number
1-31719
Entity Tax Identification Number
13-4204626
Trading Symbol
MOH
Security Exchange Name
NYSE
Document Period End Date
Apr. 22, 2026
Entity Registrant Name
MOLINA HEALTHCARE, INC.
City Area Code
562
Local Phone Number
435-3666
Written Communications
false
Soliciting Material
false
Pre-commencement Tender Offer
false
Pre-commencement Issuer Tender Offer
false
Amendment Flag
false
Entity Address, Address Line One
200 Oceangate, Suite 100,
Entity Address, City or Town
Long Beach,
Entity Address, State or Province
CA
Entity Address, Postal Zip Code
90802
X
- Definition
Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
No definition available.
+ Details
Name:
dei_AmendmentFlag
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Area code of city
+ References
No definition available.
+ Details
Name:
dei_CityAreaCode
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Cover page.
+ References
No definition available.
+ Details
Name:
dei_CoverAbstract
Namespace Prefix:
dei_
Data Type:
xbrli:stringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
No definition available.
+ Details
Name:
dei_DocumentPeriodEndDate
Namespace Prefix:
dei_
Data Type:
xbrli:dateItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
No definition available.
+ Details
Name:
dei_DocumentType
Namespace Prefix:
dei_
Data Type:
dei:submissionTypeItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Address Line 1 such as Attn, Building Name, Street Name
+ References
No definition available.
+ Details
Name:
dei_EntityAddressAddressLine1
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the City or Town
+ References
No definition available.
+ Details
Name:
dei_EntityAddressCityOrTown
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Code for the postal or zip code
+ References
No definition available.
+ Details
Name:
dei_EntityAddressPostalZipCode
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the state or province.
+ References
No definition available.
+ Details
Name:
dei_EntityAddressStateOrProvince
Namespace Prefix:
dei_
Data Type:
dei:stateOrProvinceItemType
Balance Type:
na
Period Type:
duration
X
- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityCentralIndexKey
Namespace Prefix:
dei_
Data Type:
dei:centralIndexKeyItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Indicate if registrant meets the emerging growth company criteria.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityEmergingGrowthCompany
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
No definition available.
+ Details
Name:
dei_EntityFileNumber
Namespace Prefix:
dei_
Data Type:
dei:fileNumberItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Two-character EDGAR code representing the state or country of incorporation.
+ References
No definition available.
+ Details
Name:
dei_EntityIncorporationStateCountryCode
Namespace Prefix:
dei_
Data Type:
dei:edgarStateCountryItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityRegistrantName
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityTaxIdentificationNumber
Namespace Prefix:
dei_
Data Type:
dei:employerIdItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Local phone number for entity.
+ References
No definition available.
+ Details
Name:
dei_LocalPhoneNumber
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 13e
-Subsection 4c
+ Details
Name:
dei_PreCommencementIssuerTenderOffer
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14d
-Subsection 2b
+ Details
Name:
dei_PreCommencementTenderOffer
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Title of a 12(b) registered security.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
+ Details
Name:
dei_Security12bTitle
Namespace Prefix:
dei_
Data Type:
dei:securityTitleItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the Exchange on which a security is registered.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection d1-1
+ Details
Name:
dei_SecurityExchangeName
Namespace Prefix:
dei_
Data Type:
dei:edgarExchangeCodeItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14a
-Subsection 12
+ Details
Name:
dei_SolicitingMaterial
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Trading symbol of an instrument as listed on an exchange.
+ References
No definition available.
+ Details
Name:
dei_TradingSymbol
Namespace Prefix:
dei_
Data Type:
dei:tradingSymbolItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230
-Section 425
+ Details
Name:
dei_WrittenCommunications
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration